Working
with patient organisations

At present the number of European patients able to access medicinal cannabis is below 100,000. However, as governments review and revise their guidelines, over 30 million patients may be able to access medicinal cannabis over the next 10 years. This represents a massive unmet need for medicinal cannabis treatments, across a broad range of medical conditions.

Our vision is to enable…

Removing the regulatory and prescribing hurdles of medicinal cannabis in the EU and member states will enable innovative products to reach patients in a timely manner. But this requires co-operation and cross-working between the EUMCA and the wider industry stakeholders, including:

 

  • Working with governments and healthcare professionals to assist an aid in their understanding of the benefits of cannabis for medicinal purposes
  • Working through, and with patient organisations to reduce inequalities for patients accessing medicinal cannabis-based medicines throughout the EU
  • Working and collaborating with medical research charities and patient organisations to widen our scientific understanding on the benefits of medicinal cannabis and develop ethical, comprehensive educational materials which provide balanced, scientific information on its benefits
  • Creating a transparent, credible and evidence-based knowledge exchange between medicinal cannabis stakeholders and patient organisations. Ensuring that all key marketing communications are presented to patients in a standardised and ethical manner

 

These important collaborations ensure that the patient is at the heart of what we do as an industry, in order to deliver more impactful medicinal cannabis treatments in response to a broad range of medical conditions.

Our vision is to enable…

Removing the regulatory and prescribing hurdles of medicinal cannabis in the EU and member states will enable innovative products to reach patients in a timely manner. But this requires co-operation and cross-working between the EUMCA and the wider industry stakeholders, including:

 

  • Working with governments and healthcare professionals to assist an aid in their understanding of the benefits of cannabis for medicinal purposes
  • Working through, and with patient organisations to reduce inequalities for patients accessing medicinal cannabis-based medicines throughout the EU
  • Working and collaborating with medical research charities and patient organisations to widen our scientific understanding on the benefits of medicinal cannabis and develop ethical, comprehensive educational materials which provide balanced, scientific information on its benefits
  • Creating a transparent, credible and evidence-based knowledge exchange between medicinal cannabis stakeholders and patient organisations. Ensuring that all key marketing communications are presented to patients in a standardised and ethical manner

These important collaborations ensure that the patient is at the heart of what we do as an industry, in order to deliver more impactful medicinal cannabis treatments in response to a broad range of medical conditions.

Removing the regulatory and prescribing hurdles of medicinal cannabis in the EU and member states will enable innovative products to reach patients in a timely manner. But this requires co-operation and cross-working between the EUMCA and the wider industry stakeholders, including:

  • Working with governments and healthcare professionals to assist an aid in their understanding of the benefits of cannabis for medicinal purposes
  • Working through, and with patient organisations to reduce inequalities for patients accessing medicinal cannabis-based medicines throughout the EU
  • Working and collaborating with medical research charities and patient organisations to widen our scientific understanding on the benefits of medicinal cannabis and develop ethical, comprehensive educational materials which provide balanced, scientific information on its benefits
  • Creating a transparent, credible and evidence-based knowledge exchange between medicinal cannabis stakeholders and patient organisations. Ensuring that all key marketing communications are presented to patients in a standardised and ethical manner

These important collaborations ensure that the patient is at the heart of what we do as an industry, in order to deliver more impactful medicinal cannabis treatments in response to a broad range of medical conditions.

Arrange a company visit
or contact us

Our membership team will be in touch to coordinate.

Or call +32 233 90 281

+32 233 90 281

info@eumca.org

EUMCA, Brussel, Belgium

Copyright ©2019 EUROPEAN MEDICINAL CANNABIS ASSOCIATION

Address: EUMCA, Immobilière du Noyer S.A.
Avenue Adolphe Lacomblé 69-71
B-1030 Bruxelles

Phone: +32 233 90 281

Website by
Copyright ©2019 EUROPEAN MEDICINAL CANNABIS ASSOCIATION

Address: EUMCA, Immobilière du Noyer S.A.
Avenue Adolphe Lacomblé 69-71
B-1030 Bruxelles

Phone: +32 233 90 281

Website by

WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly